Pricing Log in Create free account
Friday 6 November 2026 Export ATRA’s income statement to Excel — free account

Atara Biotherapeutics, Inc.

ATRA Healthcare Biotechnology

Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024.

Revenue
−96.4%
EPS
−260.0%
Free cash flow
+52.1%

Quarter to June 2026, against a year earlier

7.94 0.02 −0.25%
Market cap
$79.9M
P/E
0.0×
Fwd P/E
−8.1×
Dividend yield
—
F-score
5/9
Altman Z
−125.91
Beneish M
16.88
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 5.74
Sold, $m 3.79
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 1 — — — 1 — —
Sell — 1 — 2 — 3 — — 1 — — —
Insider Ownership 53.90%

Capital & Financial Ratios $m

Size
Market Cap 79.90
Revenue ttm 6.19
Net income ttm (16.69)
Free cash flow ttm (21.89)
Net debt Q (9.87)
Valuation
P/E 0.00
Forward P/E (8.09) (negative: loss-making)
Price / sales 19.27 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 1.98 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (24.71)
Growth
Revenue growth Q −96.42% (below 0%: shrinking)
Operating income growth Q −247.64% (below 0%: shrinking)
EPS, this year −126.90% (below 0%: weak)
EPS, next year A +236.15% (at or above 15%: strong)
Revenue, next year A −97.64% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +58.27% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 17.7×, against a ten-year median of 1.4×; over the ten years it ranged from −10.6× in 2023 to 54.3× in 2021.
P/S against its own 10 years 75.04%
10-year low 10-year high
EV/Sales against its own 10 years 84.70%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 52 43 8 10
Receivables 34 1 1 0
Inventory 10 11 — —
Other 6 10 2 3
102 65 12 14
2023 2024 2025 Q'26
Payables 4 4 0 1
ST’ Debt — — — —
Other 32 21 13 4
142 135 15 7

Compound Annual Growth %

10y 5y 3y
Sales — — 23.85%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q4 FY25 Estimate −0.09 Actual −0.25

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY24 −3.82 −1.19 Beat by 2.63
Q1 FY25 −3.07 3.50 Beat by 6.57
Q3 FY25 −0.83 −0.32 Beat by 0.51
Q4 FY25 −0.09 −0.25 Miss by 0.16

EPS $

Mar Jun Sep Dec Year
’26 (0.29) (0.32) — — —
’25 3.50 0.19 (0.32) (0.25) 2.57
’24 (5.75) (3.10) (2.93) (1.19) (11.41)
’23 (18.00) (17.00) (16.50) (14.00) (65.25)
’22 (21.75) 4.50 (20.50) (18.00) (56.00)
’21 (21.50) (22.75) (22.50) (24.00) (90.75)
’20 (30.00) (28.50) (23.00) (23.75) (103.75)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1 1 — — —
’25 98 18 3 2 121
’24 27 29 40 33 129
’23 1 1 2 4 9
’22 7 52 4 0 64
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (28) (7) (10) (6) (51)
’24 (30) (11) (4) (24) (69)
’23 (38) (53) (51) (50) (193)
’22 (85) (64) (65) (57) (270)
’21 (66) (62) (59) (34) (221)
’20 (67) (57) (53) (4) (181)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (28) (7) (10) (5) (50)
’24 (30) (11) (4) (25) (69)
’23 (39) (53) (52) (50) (194)
’22 (87) (65) (65) (57) (275)
’21 (68) (64) (63) (37) (231)
’20 (68) (59) (53) (5) (185)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — 20 64 9 129 121 6 +56.1% 3 41 23 (42.8%)
Gross margin, % 0.00 0.00 0.00 0.00 0.00 100.00 100.00 (3.65) 83.71 82.44 91.38 +82.4 pt
EBT (79) (120) (231) (291) (307) (340) (228) (276) (85) 33 (17) n/m
EBT margin, % 0.00 0.00 0.00 0.00 0.00 (1,672.05) (359.10) (3,220.70) (66.24) 27.09 (268.95) +27.1 pt
Net income (79) (119) (231) (291) (307) (340) (228) (276) (85) 33 (17) n/m
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 5.43 15.58 2.02 17.22 9.63 0.41 n/m
Earnings (68.75) (100.00) (131.75) (141.75) (103.75) (90.75) (56.00) (65.25) (11.41) 2.61 (1.18) n/m
Cash flow (52.23) (73.25) (102.59) (114.81) (61.09) (58.86) (66.29) (45.56) (9.18) (4.06) (1.46) (24.7%)
Capex (2.63) (16.94) (20.50) (2.71) (1.53) (2.82) (1.03) (0.28) (0.03) 0.08 0.00 n/m
Free cash flow (54.86) (90.19) (123.09) (117.53) (62.62) (61.68) (67.32) (45.84) (9.21) (3.99) (1.46) (25.3%)
Book value 220.77 148.90 193.37 141.69 156.25 74.63 31.04 (23.43) (12.99) (3.07) (2.46) n/m
Shares, m 1 1 2 2 3 4 4 4 7 13 14 +30.4%
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 0.00 5.72 0.00 1.1
P/S — — — — — 72.58 5.26 5.93 0.77 1.88 19.27 17.3
P/B — — — — — 5.28 2.64 0.00 0.00 0.00 0.00 1.6
EV/Sales — — — — — 54.33 1.44 (0.12) 0.44 1.81 17.68 11.6
EV/FCF — — — — — (4.78) (0.33) 0.01 (0.83) (4.36) (5.20) (2.1)
Cash, $m
Cash, $m Operating cash flow (60) (88) (180) (236) (181) (221) (270) (193) (69) (51) (22) (1.8%)
Capex (3) (20) (36) (6) (5) (11) (4) (1) 0 1 1 n/m
Free cash flow (63) (108) (216) (241) (185) (231) (275) (194) (69) (50) (22) (2.5%)
Balance, $m
Balance, $m Working capital 251 145 282 236 440 279 216 (40) (70) (3) 7 n/m
Net debt (256) (166) (310) (259) (501) (371) (243) (52) (43) (8) (10) (31.5%)
Shareholders’ equity 254 178 339 291 462 280 127 (99) (97) (39) (37) n/m
Returns, %
Returns, % ROA (26.85) (49.61) (75.69) (79.20) (65.86) (64.41) (54.06) (101.91) (62.20) 50.55 (57.62) +77.4 pt
ROIC 0.00 (656.28) (510.45) (587.08) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (27.79) (55.37) (89.29) (92.43) (81.43) (91.69) (112.39) (2,014.86) 86.92 (48.15) 46.33 (20.4) pt
People
People Employees 96 185 311 393 437 578 334 225 153 14 — (19.3%)
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.04 0.19 0.04 0.84 8.63 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Atara Biotherapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RLYB Rallybio Corporation $84.5M 3.3× — (loss-making) 0.00% n/m +65.25% (above 0%: growing) 100.00% 0.00% Compare
EQ Equillium, Inc. $84.3M — (loss-making) — (loss-making) −52.32% (below 0%: shrinking) n/m −38.67% (below 0%: shrinking) 100.00% 0.00% Compare
GNLX Genelux Corporation $82.4M — (loss-making) — (loss-making) — n/m −11.18% (below 0%: shrinking) 100.00% 0.00% Compare
KZIA Novogen Limited $80.0M — (loss-making) — (loss-making) — −32.67% (below 0%: shrinking) −51.71% (below 0%: shrinking) 0.00% 0.00% Compare
ATRA Atara Biotherapeutics, Inc. $79.9M — (loss-making) — (loss-making) −96.42% (below 0%: shrinking) n/m +52.10% (above 0%: growing) 69.68% (749.21%)
TLSA Tiziana Life Sciences Ltd $79.6M — (loss-making) — — −258.11% (below 0%: shrinking) +18.03% (above 0%: growing) 0.00% — Compare
TNXP Tonix Pharmaceuticals Holding Corp. $78.9M — (loss-making) — (loss-making) +577.88% (above 0%: growing) n/m −178.84% (below 0%: shrinking) 94.81% (314.05%) Compare
NRXS Neuraxis, Inc. $76.7M — (loss-making) — (loss-making) +115.71% (above 0%: growing) n/m +29.76% (above 0%: growing) 85.87% (110.16%) Compare
CLLS Cellectis S.A. $74.5M — (loss-making) — −62.05% (below 0%: shrinking) n/m −36.95% (below 0%: shrinking) 100.00% (340.69%) Compare
Median of peers $79.8M — — 0.00% — −24.06% 97.41% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 24 April 2026

Ownership

Directors and executive officers, together 41.20%
Entities affiliated with Panacea Innovation Limited 19.90%
James Huang 19.90%
Adiumentum Capital Fund I LP 19.40%
Gregory A. Ciongoli 19.40%
Redmile Group LLC 9.90%
Entities affiliated with EcoR1 Capital, LLC 9.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Atara Biotherapeutics, Inc. (ATRA) Latest News

14 Oct

Impact 4 · · Business Wire

30 Sep

Impact 4 · · Business Wire

12 Aug

Impact 3 ·

21 May

Impact 3 · · Zacks

12 May

Impact 3 · · Business Wire

7 May

Impact 4 · · InvestorsHub
Impact 4 · · Business Wire

16 Mar

Impact 4 · · Business Wire
Impact 3 · · Associated Press Finance

12 Mar

Impact 4 · · Business Wire

3 Mar

Impact 4 ·
Impact 4 · · biopharmadive.com

23 Feb

Impact 3 · · Business Wire

12 Jan

Impact 4 · · Business WireTipRanksZacksZacksSimply Wall St.MT NewswiresMotley FoolZacks

12 Nov

Impact 3 · · Associated Press Finance
Impact 3 · · Business Wire

7 Nov

Impact 3 · · Zacks

3 Nov

Impact 4 ·

25 Sep

Impact 3 ·

3 Sep

Impact 3 ·

19 Aug

Impact 3 · · pharmavoice.com

14 Aug

Impact 4 · · Simply Wall St.

11 Aug

Impact 3 ·
Impact 3 ·

5 Aug

Impact 4 ·

24 Jul

Impact 4 ·
Impact 4 ·

15 Jul

Impact 4 · · PR Newswire
Impact 3 · · biopharmadive.com

14 Jul

Impact 4 · · Business Wire
stockrow.com/ATRA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com